Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.

Officials with the FDA have granted approval to entrectinib (Rozlytrek, Genentech) for 2 different cancer indications.

Top news of the day from across the health care landscape.

HIV-related immunosuppression may contribute to an elevated risk of cancer-related morbidity in elderly patients with the disease.

If approved, acalabrutinib (Calquence, AstraZeneca) will offer a chemotherapy-free treatment option for adults with chronic lymphocytic leukemia.

An analysis of a quality improvement project at an oncology specialty pharmacy showed that pharmacist interventions can reduce financial toxicity for patients.

Top news of the day from across the health care landscape.

High body mass index is associated with an increased risk of chronic diseases such as type 2 diabetes, cancer, musculoskeletal, and respiratory conditions.

Artificial intelligence able to recognize patterns in gene sequences and molecular data from breast cancer, which oncologists are now evaluating in clinical trials.

A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.

Top news of the day from across the health care landscape.

The number of first-degree relatives affected by blood cancer and age of diagnosis may contribute to the likelihood of a family member’s risk of being diagnosed with the same disease.

Investigators believe that urine sampling can be used to diagnose and treat bladder cancer.

Top news of the day from across the health care landscape.

In an ideal world, how would you hypothesize that technology might be able to solve all of your problems?

Doug Long, MBA, vice president of industry relations at IQVIA, discusses how vertical integration will affect health care delivery.

Galcanezumab-gnlm (Emgality, Eli Lilly) may be an effective option for patients who failed previous migraine preventive treatments.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The phase 3 IMvigor130 study is the first to assess a cancer immunotherapy combination in previously untreated advanced bladder cancer.

By searching for hyperactive cell signals in primary effusion lymphoma, researchers were able to find a pathway that can be blocked to limit tumor growth.

Top news of the day from across the health care landscape.

The conference will take place in conjunction with the 7th National Association of Specialty Pharmacy Annual Meeting & Expo.

A regimen of afatinib as a first-line treatment followed by osimertinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer was found to significantly improve overall survival.

Identifying gene-pair relationships may help scientists understand why mutations in certain genes lead to cancer in certain tissues.

Top news of the day from across the health care landscape.

Officials with the FDA are assessing data accuracy issues related to Zolgensma, but have no major concerns about the spinal muscular atrophy treatment remaining on the market.